Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma.

Gupta S, McCann L, Chan YGY, Lai EW, Wei W, Wong PF, Smithy JW, Weidler J, Rhees B, Bates M, Kluger HM, Rimm DL.

J Immunother Cancer. 2019 Sep 18;7(1):254. doi: 10.1186/s40425-019-0731-9.

2.

Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma.

Wong PF, Wei W, Gupta S, Smithy JW, Zelterman D, Kluger HM, Rimm DL.

J Immunother Cancer. 2019 Jul 23;7(1):194. doi: 10.1186/s40425-019-0675-0.

3.

High-Plex Predictive Marker Discovery for Melanoma Immunotherapy-Treated Patients Using Digital Spatial Profiling.

Toki MI, Merritt CR, Wong PF, Smithy JW, Kluger HM, Syrigos KN, Ong GT, Warren SE, Beechem JM, Rimm DL.

Clin Cancer Res. 2019 Sep 15;25(18):5503-5512. doi: 10.1158/1078-0432.CCR-19-0104. Epub 2019 Jun 12.

PMID:
31189645
4.

Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma.

Wong PF, Wei W, Smithy JW, Acs B, Toki MI, Blenman KRM, Zelterman D, Kluger HM, Rimm DL.

Clin Cancer Res. 2019 Apr 15;25(8):2442-2449. doi: 10.1158/1078-0432.CCR-18-2652. Epub 2019 Jan 7.

PMID:
30617133
5.

Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations.

Toki MI, Mani N, Smithy JW, Liu Y, Altan M, Wasserman B, Tuktamyshov R, Schalper K, Syrigos KN, Rimm DL.

J Thorac Oncol. 2018 Dec;13(12):1884-1896. doi: 10.1016/j.jtho.2018.09.012. Epub 2018 Sep 26.

PMID:
30267840
6.

Postneoadjuvant adjuvant chemotherapy in resected N1 non-small cell lung cancer with residual nodal disease.

Smithy JW, Rosen JE, Gao SJ, Kim AW.

J Surg Oncol. 2017 Dec;116(8):1193-1196. doi: 10.1002/jso.24779.

PMID:
29314062
7.

Nuclear IRF-1 expression as a mechanism to assess "Capability" to express PD-L1 and response to PD-1 therapy in metastatic melanoma.

Smithy JW, Moore LM, Pelekanou V, Rehman J, Gaule P, Wong PF, Neumeister VM, Sznol M, Kluger HM, Rimm DL.

J Immunother Cancer. 2017 Mar 21;5:25. doi: 10.1186/s40425-017-0229-2. eCollection 2017.

8.

A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1.

Gaule P, Smithy JW, Toki M, Rehman J, Patell-Socha F, Cougot D, Collin P, Morrill P, Neumeister V, Rimm DL.

JAMA Oncol. 2017 Feb 1;3(2):256-259. doi: 10.1001/jamaoncol.2016.3015.

9.

Publication of pivotal efficacy trials for novel therapeutic agents approved between 2005 and 2011: a cross-sectional study.

Smithy JW, Downing NS, Ross JS.

JAMA Intern Med. 2014 Sep;174(9):1518-20. doi: 10.1001/jamainternmed.2014.3438. No abstract available.

Supplemental Content

Loading ...
Support Center